Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENABLE: Alpibectir in Pulmonary Tuberculosis
NCT06748937Phase 2Recruiting
- Sponsor
- TASK Foundation
- Start
- Mar 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpibectir in pulmonary tuberculosis (TB), sponsored by TASK Foundation. Started Mar 2025; status: recruiting.
02
Drugs
alpibectir
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT06748937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748937.